

**Supplementary figures and tables.**

	<b>Value</b>	<b>TASQ ITT (N=134)</b>	<b>Placebo ITT (N=67)</b>	<b>TASQ PCWG2 Bone Mets (N=92)</b>	<b>Placebo PCWG2 Bone Mets (N=44)</b>
<b>Age (Years)</b>	Mean (SD)	72.3 (9.6)	73.2 (8.7)	72.6 (9.9)	75.0 (7.3)
<b>Pain (VAS)</b>	No Pain	97 (72%)	59 (89%)	64 (70%)	37 (84%)
	VAS 1-4	37 (28%)	7 (11%)	28 (30%)	7 (16%)
<b>Karnofsky Score</b>	>80%	120 (90%)	59 (88%)	82 (89%)	39 (89%)
	<=80%	14 (10%)	8 (12%)	10 (11%)	5 (11%)
<b>PSA Level (ug/L)</b>	Median (SD)	29 (36)	19 (20)	27 (32)	20 (21)
<b>Historic PSA DT (Mo)</b>	Median (SD)	4.2 (2.8)	5.1 (3.1)	4.0 (2.9)	4.4 (3.3)
<b>LDH (U/L)</b>	Median (SD)	202 (48)	206 (46)	193 (47)	214 (55)
<b>Alk Phos (U/L)</b>	Median (SD)	98 (41)	87 (35)	102 (43)	90 (43)
<b>Hemoglobin (g/L)</b>	Median (SD)	129 (15)	132 (13)	131 (15)	132 (14)
<b>Visceral disease</b>	N (%)	32 (24)	10 (15)	0	0

**SupplementaryTable 1.** Baseline characteristics of patients in the trial and subgroups investigated, including parameters used in the multivariate analysis. The following abbreviations are used: ITT=Intention to treat, VAS=visual analog scale (linear pain rating of 0-10), PSA=prostate specific antigen, PSADT=PSA doubling time, PCWG2=PC Working Group 2 Guidelines, SD=standard deviation.

**Supplementary table 2.** Characteristics at baseline and at the end of open-label treatment for patients treated in the placebo group during the double blind phase of the trial, grouped according to whether the subject received open label tasquinimod or not.

		Entering open label treatment (N=41)		Not entering open label treatment (N=26)	
		Baseline	End Double blind	Baseline	End Double blind
<b>Age (Years)</b>	Mean (SD)	72.9 (9.3)	73.4 (9.2)	73.6 (8.0)	73.8 (8.1)
<b>Pain (VAS)</b>	No Pain	38 (93%)	27 (66%)	21 (81%)	24 (59%)
	VAS 1-4	2 (5%)	14 (34%)	5 (19%)	17 (41%)
<b>Karnofsky Score</b>	>80%	40 (98%)	36 (88%)	19 (73%)	16 (62%)
	<=80%	1 (2%)	5 (12%)	7 (27%)	10 (38%)
<b>PSA Level (ug/L)</b>	Median (SD)	19 (20)	48 (60)	17 (20)	51 (67)
<b>PSA DT (Mo)</b>	Median (SD)	5.4 (3.2)	5.5 (4.6)	4.3 (3.0)	2.7 (1.6)
<b>LDH (U/L)</b>	Median (SD)	207 (45)	206 (47)	205 (50)	228 (76)
<b>Alkaline Phosphatase (U/L)</b>	Median (SD)	88 (39)	94 (47)	84 (39)	122 (74)
<b>Hemoglobin (g/L)</b>	Median (SD)	131 (15)	131 (17)	133 (12)	127 (17)
<b>Visceral disease</b>	N (%)	6 (15%)	10 (24%)	4 (15%)	7 (27%)